- Home
- AIRS vs AMRN Comparison
AIRS vs AMRN Comparison
Compare AIRS & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRS
- AMRN
- Stock Information
- Founded
- AIRS 2012
- AMRN 1989
- Country
- AIRS United States
- AMRN Ireland
- Employees
- AIRS N/A
- AMRN N/A
- Industry
- AIRS Medical/Nursing Services
- AMRN Biotechnology: Pharmaceutical Preparations
- Sector
- AIRS Health Care
- AMRN Health Care
- Exchange
- AIRS Nasdaq
- AMRN Nasdaq
- Market Cap
- AIRS 166.3M
- AMRN 317.1M
- IPO Year
- AIRS 2021
- AMRN 1993
- Fundamental
- Price
- AIRS $6.15
- AMRN $14.82
- Analyst Decision
- AIRS Hold
- AMRN Strong Sell
- Analyst Count
- AIRS 3
- AMRN 1
- Target Price
- AIRS $3.75
- AMRN $12.00
- AVG Volume (30 Days)
- AIRS 512.2K
- AMRN 49.5K
- Earning Date
- AIRS 11-07-2025
- AMRN 10-29-2025
- Dividend Yield
- AIRS N/A
- AMRN N/A
- EPS Growth
- AIRS N/A
- AMRN N/A
- EPS
- AIRS N/A
- AMRN N/A
- Revenue
- AIRS $165,109,000.00
- AMRN $219,361,000.00
- Revenue This Year
- AIRS N/A
- AMRN N/A
- Revenue Next Year
- AIRS $5.14
- AMRN N/A
- P/E Ratio
- AIRS N/A
- AMRN N/A
- Revenue Growth
- AIRS N/A
- AMRN N/A
- 52 Week Low
- AIRS $1.53
- AMRN $7.08
- 52 Week High
- AIRS $9.20
- AMRN $17.49
- Technical
- Relative Strength Index (RSI)
- AIRS 49.58
- AMRN 45.25
- Support Level
- AIRS $5.61
- AMRN $14.54
- Resistance Level
- AIRS $6.41
- AMRN $15.46
- Average True Range (ATR)
- AIRS 0.41
- AMRN 0.47
- MACD
- AIRS -0.04
- AMRN -0.05
- Stochastic Oscillator
- AIRS 46.83
- AMRN 26.89
About AIRS AirSculpt Technologies Inc.
AirSculpt Technologies Inc is a national provider of body contouring procedures delivering a premium consumer experience under its brand Elite Body Sculpture. Elite Body Sculpture, provides custom body contouring using the proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure. The company has one operating and reportable segment, direct medical procedure services.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.